Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Short Interest Update

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,833,866 shares, an increase of 139.9% from the June 15th total of 1,181,288 shares. Currently, 11.4% of the company’s stock are sold short. Based on an average daily trading volume, of 824,119 shares, the short-interest ratio is currently 3.4 days.

Whitehawk Therapeutics Stock Performance

Shares of WHWK stock opened at $3.84 on Tuesday. The firm has a market cap of $189.89 million, a price-to-earnings ratio of -2.29 and a beta of 0.77. Whitehawk Therapeutics has a 52 week low of $1.57 and a 52 week high of $5.49. The firm’s 50-day simple moving average is $4.28 and its two-hundred day simple moving average is $3.62.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its earnings results on Thursday, May 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. Analysts forecast that Whitehawk Therapeutics will post -1.37 earnings per share for the current year.

Insider Buying and Selling

In other Whitehawk Therapeutics news, CFO Scott M. Giacobello sold 141,600 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $4.13, for a total value of $584,808.00. Following the completion of the sale, the chief financial officer owned 295,224 shares in the company, valued at approximately $1,219,275.12. This trade represents a 32.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 49.90% of the company’s stock.

Hedge Funds Weigh In On Whitehawk Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of WHWK. Quadrature Capital Ltd purchased a new stake in Whitehawk Therapeutics in the fourth quarter worth $28,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Whitehawk Therapeutics during the 1st quarter valued at $40,000. Geode Capital Management LLC lifted its position in shares of Whitehawk Therapeutics by 11.4% during the 4th quarter. Geode Capital Management LLC now owns 425,440 shares of the company’s stock valued at $1,030,000 after buying an additional 43,686 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Whitehawk Therapeutics during the 3rd quarter valued at $84,000. Finally, Jane Street Group LLC grew its stake in shares of Whitehawk Therapeutics by 177.3% during the 4th quarter. Jane Street Group LLC now owns 69,931 shares of the company’s stock worth $169,000 after acquiring an additional 44,716 shares during the period. 52.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on WHWK shares. Citizens Jmp assumed coverage on Whitehawk Therapeutics in a report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 target price for the company. B. Riley Financial initiated coverage on Whitehawk Therapeutics in a report on Thursday, June 25th. They set a “buy” rating and a $10.00 price target on the stock. Oppenheimer reissued an “outperform” rating and issued a $7.00 price objective on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. Leerink Partners assumed coverage on Whitehawk Therapeutics in a research note on Monday. They issued an “outperform” rating and a $9.00 price objective for the company. Finally, Wall Street Zen lowered Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Whitehawk Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $8.20.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.